Overview

Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

This study is conducted in Asia. The aim of this study is to assess the efficacy, safety and convenience of the use of Mixtard® 30 NovoLet® used alone or combined with oral hypoglycaemic agent (OHA) in the management of type 2 diabetes mellitus in an out-patient setting.

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Insulin
Insulin, Globin Zinc
Insulin, pork; isophane insulin, pork drug combination 30:70